Clinical trials: Immunity, Cellular
Vaccine
Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals.
- Trial name
- NCT07672626
- Testing
- the tested vaccine, the control vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Lyme Disease, Borrelia Infections
Borrelia B-cell Diagnostics
The investigators propose a single center, prospective observational study in children with Lyme disease (LD), the Borrelia B-cell diagnostics (BRILLIANT) study, to assess the immune response against Borrelia burgdorferi (Bb)…
- Trial name
- BRILLIANT (NCT06045416)
- Testing
- venous blood puncture
- Where
- Switzerland
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Influenza
Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.
- Trial name
- NCT03023683
- Testing
- FluMist®
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Stanford University
Immune Response to 3 Approaches
Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma
The purpose of this study is to compare changes in the body's self-defense (immune response) after two different treatments for small kidney tumors: 1) Cryoablation (freezing) therapy in which the tumor and a margin of normal…
- Trial name
- NCT03409224
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Influenza A Subtype H5N1 Infection
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the…
- Trial name
- HIPCVAX-010S (NCT03701061)
- Testing
- Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines
The purpose of the study is to evaluate safety and compare how the body reacts to 2 different strengths of the Clade (specific type of H5N1 virus) 2 H5N1 flu vaccine when given as a single vaccination with a high dose (90 mcg) or…
- Trial name
- NCT01086566
- Testing
- Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clinically Isolated Syndrome, Multiple Sclerosis
Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome
The primary purpose of this study is to assess the immune response to vitamin D supplementation at two doses (5,000 IU and 10,000 IU daily) in both healthy controls and patients with clinically isolated syndrome compared to…
- Trial name
- CISAVID (NCT01728922)
- Testing
- 5000IU vitamin D, 10000IU vitamin D
- Where
- Ireland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Meningitis, Septicemia
Understanding the Immune Response to Meningitis Vaccines
The purpose of the study is to evaluate and compare the immune response to two vaccines against 4 related bacteria: meningococcal serogroups A, C, W-135 and Y.
- Trial name
- NCT00901940
- Testing
- Meningococcal (Groups A, C, Y and W-135) Conjugate, Meningococcal polysaccharide A, C, Y and W135 and Menveo
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
VKH Syndrome
Immune Profile of Acute VKH Patients PBMC
The investigators will collect blood samples of different courses of VKH patients for investigating immune profile, observe major immune cells number ,functional and membrane molecular changes in the course of treatment, to…
- Trial name
- IPV (NCT04025476)
- Testing
- Steroids
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Chlamydia
Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
This is an exploratory study in which the investigators will develop a way to identify the cell responses most strongly associated with protection against chlamydia infection. This study is not driven by a hypothesis.
- Trial name
- NCT00970749
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Immunity to Influenza Vaccine
Cell Mediated Immunity in Older Adults
This study is to study the immune response to the flu vaccine in people 65 years old and older. Only adults 65 years old and older and who are getting their flu vaccine are being asked to join in this study.
- Trial name
- CMI (NCT01189123)
- Testing
- High dose influenza vaccine Sanofi-Pasteur, fluzone by sanofi pasteur
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Whooping Cough
A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
The study should be leaded as a randomized double-blind placebo-controlled comparative research of potency and safety of a GamLPV, a live intranasal Bordetella pertussis vaccine, using two dosing schedules and methods of…
- Trial name
- NCT04036526
- Testing
- Vaccine GamLPV
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Japanese Encephalitis Vaccine
Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.
The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis vaccine in elderly subjects (above 60 years of age) in comparison to a young study group.
- Trial name
- NCT03971058
- Testing
- IXIARO®- Japanese Encephalitis vaccine
- Where
- 2 sites in Austria
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Immune Tolerance, Viral Infection
Immune Responses With Reduxium
Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation.
- Trial name
- NCT04525456
- Testing
- Reduxium
- Where
- 3 sites in Singapore
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ogevity Therapeutics, Inc.
Influenza
Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects
The purpose of this study is explore the antibody and cell mediated immune responses to one injection of Focetria™ pandemic influenza vaccine in healthy adults aged 18-60 years.
- Trial name
- NCT01079273
- Testing
- egg-derived A/H1N1 pandemic influenza vaccine
- Where
- Italy
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Opera CRO, a TIGERMED Group Company
Healthy
Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization
One of the major interests of this laboratory is the characterization of the cellular subpopulations involved in the triggering and immunoregulation of B lymphocytes to produce antibodies.
- Trial name
- NCT00001173
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Popular topic: Clinical study on immunogenicity and safety evaluation of sequentially enhanced immunity with recombinant Novel Coronavirus vaccine (CHO cells) Research purpose:Main purpose:To evaluate the immunogenicity of…
- Trial name
- NCT05089045
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Sexually Transmitted Diseases, Viral
Measuring Responses to Sublingual Antigens
This study is a preliminary investigation of immune responses, in the blood and in cervical \& vaginal secretions, to proteins ("antigens") taken up across the undersurface of the tongue.
- Trial name
- NCT00949572
- Testing
- Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Ovarian Neoplasms, Ovarian Cancer
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy.
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Ovarian Carcinoma, Immune Suppression
- Trial name
- RENAISSANCE (NCT06611072)
- Testing
- Bone marrow aspiration, Vena puncture, Peritoneal fluid
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Healthy Volunteers
Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients
This study will assess the effect of a different dose of the seasonal flu vaccine 2013-2015 on the immune response to improve the investigators understanding of cellular and humoral immune responses induced.
- Trial name
- NCT02746783
- Testing
- Single dose MUTAGRIP® influenza vaccine, Double dose of MUTAGRIP® influenza vaccine
- Where
- Switzerland
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University of Lausanne Hospitals